Equities

Rezolute Inc

Rezolute Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.76
  • Today's Change-0.105 / -2.16%
  • Shares traded46.13k
  • 1 Year change+519.71%
  • Beta1.0309
Data delayed at least 15 minutes, as of Nov 22 2024 14:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.

  • Revenue in USD (TTM)0.00
  • Net income in USD-69.31m
  • Incorporated2021
  • Employees59.00
  • Location
    Rezolute Inc275 Shoreline Drive, Suite 500REDWOOD CITY 94065United StatesUSA
  • Phone+1 (650) 206-4507
  • Fax+1 (302) 636-5454
  • Websitehttps://www.rezolutebio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Artiva Biotherapeutics Inc-100.00bn-100.00bn264.12m82.00--1.31----------8.28----------------------------0.001--579.21--51.15------
Poseida Therapeutics Inc150.86m-60.76m264.13m350.00--3.03--1.75-0.635-0.6351.560.89530.5064--12.88457,145.50-20.39-40.70-27.58-47.72-----40.28-233.49---6.890.4032---50.42---92.85--19.01--
Atea Pharmaceuticals Inc0.00-174.01m274.50m75.00--0.5987-----2.07-2.070.005.430.00----0.00-31.67-5.90-32.99-6.98-------38.91----0.00-------17.30------
Lexicon Pharmaceuticals Inc5.23m-216.39m278.96m285.00--1.56--53.35-0.7513-0.75130.0180.49380.01750.69553.2518,347.37-72.42-24.41-81.77-29.0193.5498.49-4,138.33-84.927.43-12.320.3588--766.19-54.71-73.74--37.68--
Tevogen Bio Holdings Inc0.0057.92m279.86m17.004.36------0.37580.37580.00-0.04520.00----0.001,217.57-----------------702.58--------99.69------
Rezolute Inc0.00-69.31m281.60m59.00--2.37-----1.27-1.270.002.050.00----0.00-58.64-50.36-62.66-53.25------------0.00-------32.19------
C4 Therapeutics Inc33.67m-105.50m283.06m145.00--1.17--8.41-1.70-1.700.52173.440.095--6.21232,193.10-29.76-25.91-33.20-29.45-----313.35-292.35----0.00---33.251.40-3.37---8.68--
Aldeyra Therapeutics Inc0.00-44.80m286.43m10.00--3.37-----0.7538-0.75380.001.430.00----0.00-33.86-36.79-39.67-40.77------------0.1522------39.47------
Vanda Pharmaceuticals Inc.190.86m-16.39m288.04m203.00--0.5322--1.51-0.2824-0.28243.299.280.29679.305.30940,187.20-2.556.61-2.957.6293.6290.55-8.5915.184.84--0.000.00-24.27-0.0496-60.02-36.96-56.77--
Absci Corp4.21m-97.67m289.57m155.00--1.45--68.83-0.9357-0.93570.04021.760.0178--3.6627,141.94-41.42---46.85-------2,321.56-----157.350.0269---0.5046---5.40------
Voyager Therapeutics Inc163.78m25.88m296.12m162.009.240.89669.571.810.58760.58762.946.060.4545--14.291,011,012.007.180.63788.420.8203----15.801.30----0.000.00511.16101.01385.14---5.43--
SAGE Therapeutics Inc106.40m-337.59m296.69m487.00--0.5376--2.79-5.58-5.581.769.020.1354--5.24218,478.40-42.95-21.88-48.97-23.3091.7599.63-317.29-131.50----0.00--1,024.84-0.8606-1.63---28.01--
iTeos Therapeutics Inc35.00m-121.25m296.92m157.00--0.4701--8.48-3.15-3.150.906417.290.05--1.43222,929.90-17.315.84-18.167.02-----346.4422.09----0.000.00-95.29---216.54--68.45--
Nautilus Biotechnology Inc0.00-70.21m298.84m161.00--1.34-----0.561-0.5610.001.780.00----0.00-24.29---25.05--------------0.00-------9.93------
Data as of Nov 22 2024. Currency figures normalised to Rezolute Inc's reporting currency: US Dollar USD

Institutional shareholders

47.34%Per cent of shares held by top holders
HolderShares% Held
Federated Global Investment Management Corp.as of 30 Sep 202411.28m20.17%
Nantahala Capital Management LLCas of 30 Sep 20242.58m4.61%
The Vanguard Group, Inc.as of 30 Sep 20241.91m3.42%
Blackstone Alternative Asset Management LPas of 30 Sep 20241.74m3.12%
Altium Capital Management LPas of 30 Sep 20241.70m3.04%
Affinity Asset Advisors LLCas of 30 Sep 20241.70m3.04%
Adar1 Capital Management LLCas of 30 Sep 20241.57m2.81%
Ghost Tree Capital LLCas of 30 Sep 20241.47m2.64%
Caxton Corp.as of 30 Sep 20241.32m2.36%
Sphera Funds Management Ltd.as of 30 Sep 20241.20m2.14%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.